Status:

COMPLETED

MAFLD-simplified Definition as an Optimized Risk Stratification Tool for Predicting Metabolic Outcomes

Lead Sponsor:

Ningbo No. 1 Hospital

Conditions:

Metabolic Associated Fatty Liver Disease

Eligibility:

All Genders

18-100 years

Brief Summary

Recently, a consensus was proposed by an international expert panel for the terminology changed from NAFLD to Metabolic associated fatty liver disease (MAFLD). The comprehensive criteria shift to a "p...

Detailed Description

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver diseases. It affects nearly 25% of the global population. Recently, a consensus was proposed by an international expe...

Eligibility Criteria

Inclusion

  • diagnosed ad fatty liver by ultrasound

Exclusion

  • Missing data on Ultrasound, blood glucose, BMI and metabolic status.

Key Trial Info

Start Date :

January 1 2012

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 31 2020

Estimated Enrollment :

3372 Patients enrolled

Trial Details

Trial ID

NCT04761900

Start Date

January 1 2012

End Date

December 31 2020

Last Update

February 21 2021

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

MAFLD-simplified Definition as an Optimized Risk Stratification Tool for Predicting Metabolic Outcomes | DecenTrialz